Holen Sie sich die Stockscreener-App
6.03
0.33%
0.02
Handel nachbörslich:
6.02
-0.01
-0.17%
Schlusskurs vom Vortag:
$6.01
Offen:
$6.02
24-Stunden-Volumen:
125.55K
Relative Volume:
0.42
Marktkapitalisierung:
$311.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.90M
KGV:
-11.38
EPS:
-0.53
Netto-Cashflow:
$-19.80M
1W Leistung:
+29.12%
1M Leistung:
+40.23%
6M Leistung:
-4.13%
1J Leistung:
+71.79%
1-Tages-Spanne:
$6.00
$6.14
1-Wochen-Bereich:
$4.39
$6.40
52-Wochen-Spanne:
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Vergleichen Sie DMAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.03 | 309.45M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
Applying Elliott Wave Theory to DiaMedica Therapeutics Inc.Market Growth Summary & High Accuracy Trade Signal Alerts - Newser
Can machine learning forecast DiaMedica Therapeutics Inc. recoveryTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - Newser
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
Identifying reversal signals in DiaMedica Therapeutics Inc.Product Launch & Accurate Technical Buy Alerts - Newser
Intrinsic Value of DiaMedica Therapeutics Inc. Stock: Is It Undervalued or OvervaluedJuly 2025 Weekly Recap & Technical Analysis for Trade Confirmation - Newser
Pattern recognition hints at DiaMedica Therapeutics Inc. upsideJuly 2025 Spike Watch & Accurate Buy Signal Alerts - Newser
Multi factor analysis applied to DiaMedica Therapeutics Inc.Insider Selling & Consistent Profit Alerts - Newser
Full technical analysis of DiaMedica Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - Newser
Custom strategy builders for tracking DiaMedica Therapeutics Inc.Market Risk Summary & Community Consensus Picks - Newser
Technical signs of recovery in DiaMedica Therapeutics Inc.Long Setup & Free Growth Oriented Trading Recommendations - Newser
Statistical indicators supporting DiaMedica Therapeutics Inc.’s strengthTrend Reversal & Safe Entry Momentum Tips - Newser
What indicators show strength in DiaMedica Therapeutics Inc.Analyst Downgrade & Risk Managed Investment Signals - Newser
What to expect from DiaMedica Therapeutics Inc. in the next 30 daysGap Up & Reliable Entry Point Trade Alerts - Newser
Is this a good reentry point in DiaMedica Therapeutics Inc.July 2025 Earnings & Reliable Entry Point Alerts - Newser
Technical analysis overview for DiaMedica Therapeutics Inc. stockJuly 2025 PostEarnings & Weekly Breakout Opportunity Watchlist - Newser
Will DiaMedica Therapeutics Inc. see short term momentumWeekly Volume Report & Free Community Consensus Stock Picks - Newser
What’s the MACD signal for DiaMedica Therapeutics Inc.Entry Point & Weekly Watchlist for Hot Stocks - classian.co.kr
DiaMedica Therapeutics Inc (DMAC) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2025 Earnings Call Transcript - Insider Monkey
DiaMedica advances DM199 programs with $60M cash runway and expanded clinical trials - MSN
DiaMedica Therapeutics Advances with Positive Trials and Funding - TipRanks
DiaMedica Therapeutics reports Q2 EPS (18c), consensus (19c) - MSN
DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia (NASDAQ:DMAC) - Seeking Alpha
Diamedica Therapeutics shares rise 14.94% intraday after Celcuity's positive Phase 3 trial results. - AInvest
DiaMedica Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Diamedica Therapeutics shares rise 1.92% intraday after Q2 2025 earnings call. - AInvest
Earnings call transcript: DiaMedica Therapeutics Q2 2025 shows promising trials By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Therapeutics Q2 2025 shows promising trials - Investing.com India
DiaMedica Posts Narrower Loss in Q2 - AOL.com
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics Enters Sales Agreement with TD Securities - TipRanks
DiaMedica Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can DiaMedica Therapeutics Inc. sustain its profitabilityReal-Time Trade Breakout Scanner - thegnnews.com
Screener Results Flag DiaMedica Therapeutics Inc. as OversoldROI Driven Equity Selection With Safety Emphasized - 선데이타임즈
What data driven models say about DiaMedica Therapeutics Inc.’s futureRapid Trade Forecast Based on Indicators - Newser
Momentum divergence signals in DiaMedica Therapeutics Inc. chartAutomated AI Forecast with Trading Alerts - Newser
Fair Value Estimate for DiaMedica Therapeutics: $5.11; Share Price Matches Fair Value; Analyst Price Target Exceeds Fair Value. - AInvest
Volume spikes in DiaMedica Therapeutics Inc. stock – what they meanShort-Term AI-Based Stock Price Forecast - Newser
What’s the recovery path for long term holders of DiaMedica Therapeutics Inc. - Newser
What makes DiaMedica Therapeutics Inc. stock price move sharplyFree AI Based High Gain Watchlist Scanner - Newser
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):